Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease

Diabetes and Vascular Disease Research

Volumn 9, Issue 4, 2012, Pages 301-308

  Sun, Ai Li ^a   Deng, Jing Ti ^a   Guan, Guang Ju ^a   Chen, Shi Hong ^a   Liu, Yuan Tao ^a   Cheng, Jing ^a   Li, Zhen Wei ^b   Zhuang, Xiang Hua ^a   Sun, Fu Dun ^a   Deng, Hao Ping ^c  

^a SHANDONG UNIVERSITY   (China)

^b Sanitation Superintendence Office   (China)

^c Laizhou People's Hospital   (China)

Author keywords

albuminuria; Diabetic kidney disease; dipeptidyl peptidase IV; urinary microvesicles

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL PEPTIDASE IV; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOPLASM VESICLE; DIABETIC NEPHROPATHY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROVESICLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; WESTERN BLOTTING;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CENTRIFUGATION; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOSOMES; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; LINEAR MODELS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; URINALYSIS; URINE;

EID: 84866718544     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111434318     Document Type: Article

References (30)

1. Reutens AT, Prentice L, Atkins R The epidemiology of diabetes mellitus. 2 nd ed.Chichester: John Wiley & Sons Ltd, 2008, pp. 499-518. Ekoe J, ed. Chichester: John Wiley & Sons Ltd ; 2008: 499-518.
2. 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases ; 2007: 239-254.
3. Treatment guide for diabetes. 1 st ed.Bunkodo, Tokyo: Japan Diabetes Society, 2007, pp. 68-69. Bunkodo, Tokyo: Japan Diabetes Society ; 2007: 68-69.
4. Wiseman MJ, Viberti G. Genesis and evolution of proteinuria in diabetes mellitus. Ric Clin Lab. 1985 ; 15: 9-16
5. Krempf M, du Rostu H, Murat A, et al. Radioimmunoassay of urinary albumin: early indicator of diabetic nephropathy?. Rev Med Interne. 1985 ; 6: 510-514
6. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of micro-vesicles in human urine. Proc Natl Acad Sci U S A. 2004 ; 101: 13368-13373
7. Pala L, Mannucci E, Pezzatini A, et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Comm. 2003 ; 310: 28-31
8. Whitehouse Station, NJ: Merck & Co., Inc ; 2007
9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 ; 32: 193-203
10. Deng JT, Hoylaerts MF, Nouwen EJ, et al. Purification of circulating liver plasma membrane fragments using a monoclonal antileucine aminopeptidase antibody. Hepatology (Baltimore, MD). 1996 ; 23: 445-454
11. Deng JT, Parsons PG. Solid phase immunoassay for high molecular weight alkaline phosphatase in human sera using a specific monoclonal antibody. Clin Chim Acta. 1988 ; 176: 291-301
12. Cheruvanky A, Zhou H, Pisitkun T, et al. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol. 2007 ; 292: F1657 - F1661
13. Nagatsu T, Hino M, Fuyamada H, et al. New chromogenic substrates for X-Prolyl dipeptidyl-aminopeptidase. Anal Biochem. 1976 ; 74: 466-476
14. Miranda KC, Bond DT, McKee M, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010 ; 78: 191-199
15. Gonzales PA, Pisitkun T, Hoffert JD, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2009 ; 20: 363-379
16. Conde-Vancells J, Rodriguez-Suarez E, Gonzalez E, et al. Candidate biomarkers in exosome-like vesicles purified from rat and mouse urine samples. Proteomics Clin Appl. 2010 ; 4: 416-425
17. Chatelet F, Brianti E, Ronco P, et al. Ultrastructural localization by monoclonal antibodies of brush border antigens expressed by glomeruli. I. Renal distribution. Am J Pathol. 1986 ; 122: 500-511
18. Sato K, Aytac U, Yamochi T, et al. CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. Br J Cancer. 2003 ; 89: 1366-1374
19. Sato T, Yamochi T, Aytac U, et al. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005 ; 65: 6950-6956
20. Yamochi T, Aytac U, Sato T, et al. Regulation of p38 phosphorylation and topoisomerase II alpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res. 2005 ; 65: 1973-1983
21. Mitic B, Lazarevic G, Vlahovic P, et al. Diagnostic value of the aminopeptidase N, N-acetyl-b-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail. 2008 ; 30: 896-903
22. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007 ; 66: 159-165
23. Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2009 ; 200: 53-61
24. Scherberich JE, Wiemer J, Schoeppe W. Biochemical and immunological properties of urinary angiotensinase A and dipeptidylaminopeptidase IV. Their use as markers in patients with renal cell injury. Eur J Clin Chem Clin Biochem. 1992 ; 30: 663-668
25. Augustyns K, Bal G, Thonus G, et al. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem. 1999 ; 6: 311-327
26. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005 ; 48: 1168-1172
27. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol. 2006 ; 155: 485-493
28. Meneilly GS, Demuth HU, McIntosh CHS, et al. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med. 2000 ; 17: 346-350
29. McKillop AM, Duffy NA, Lindsay JR, et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects. Diabet Res Clin Pract. 2008 ; 79: 79-85
30. Luft VC, Schmidt MI, Pankow JS, et al. Dipeptidyl peptidase IV and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2010 ; 33: 1109-1111